国际肿瘤学杂志

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (7): 545-548.doi: 10.3760/cma.j.issn.1673422X.2014.07.019

• 论著 • 上一篇    下一篇

培美曲塞联合顺铂在晚期乳腺癌中的应用


岳丽娟, 侯新丽, 薛辉, 薛玲, 高翔, 沈勇, 袁亮, 张晶晶, 朱宏财   

  1. 723000 陕西省汉中市中心医院肿瘤内科
  • 出版日期:2014-08-04 发布日期:2014-08-04
  • 通讯作者: 岳丽娟，Email: yuelijuan26@163.com E-mail:yuelijuan26@163.com

Pemetrexed in combination with cisplatin in the treatment of advanced breast cancer application

YUE  Li-Juan, HOU  Xin-Li, XUE  Hui, XUE  Ling, GAO  Xiang, SHEN  Yong, YUAN  Liang, ZHANG  Jing-Jing, ZHU  Hong-Cai   

  1. Department of Oncology，Hanzhong Central Hospital of Shanxi Province, Hanzhong 723000，China 
  • Online:2014-08-04 Published:2014-08-04
  • Contact: Yue Lijuan E-mail:yuelijuan26@163.com

PDF

1326

摘要： 目的研究培美曲塞联合顺铂方案治疗晚期乳腺癌的近期临床疗效和不良反应。方法采用信封法随机分为治疗组和对照组。治疗组18例晚期乳腺癌用培美曲塞联合顺铂方案治疗，对照组23例晚期乳腺癌用吉西他滨联合顺铂治疗，21 d为一个周期。按世界卫生组织（WHO）关于实体瘤治疗疗效评价标准和化疗毒性评价标准（CTCAE），判断近期疗效和药物的不良反应。结果治疗组的肿瘤控制率为83.3%（15/18），对照组为78.3%（18/23），两组差异无统计学意义（χ2=0.000 94，P>0.05）；而治疗组和对照组的不良反应比较，两组差异均有统计学意义（骨髓抑制χ2=9.23；疲乏χ2=4.96；恶心、呕吐χ2=4.98；腹泻χ2=4.45；皮疹χ2=5.03，P均<0.05）。结论培美曲塞联合顺铂方案对晚期乳腺癌患者具有很好的疗效，且不良反应低。

关键词: 顺铂, 乳腺肿瘤, 治疗应用

Abstract: ObjectiveTo study recent clinical efficacy and adverse reactions of pemetrexed in combination with cisplatin in the treatment of advanced breast cancer . MethodsUsing envelopes andrandomly the patients were dividing into treatment group and control group. The treatment group with 18 cases of advanced breast cancer were treated with pemetrexed and cisplatin while in the control group , 23 cases advanced breast cancer patients were treated with gemcitabine and cisplatin with 21 days as a cycle. The efficacy and adverse reactions were determined according to the WHO on Response Evaluation Criteria in Solid Tumors therapy and chemotherapy toxicity evaluation criteria. ResultsTumor control rate in the treatment group was 83.3%（15/18）,while  in the control group was 78.3%（18/23）, and the difference was not statistically significant (χ2=0.000 94，P> 0.05); while the adverse reactions differenced between the treatment group and the control group were statistically significant（bone marrow suppression χ2=9.23；fatigue χ2=4.96；nausea and vomiting χ2=4.98；diarrhea χ2=4.45；skin rash χ2=5.03，P<0.05）. ConclusionPemetrexed combined with cisplatin in patients with advanced breast cancer has a good effect, and the adverse reaction is low.

Key words: Cisplatin, Breast neoplasms, Therapeutic uses